EP2224924A4 - Compositions and methods for treating cystic fibrosis - Google Patents

Compositions and methods for treating cystic fibrosis

Info

Publication number
EP2224924A4
EP2224924A4 EP08841991A EP08841991A EP2224924A4 EP 2224924 A4 EP2224924 A4 EP 2224924A4 EP 08841991 A EP08841991 A EP 08841991A EP 08841991 A EP08841991 A EP 08841991A EP 2224924 A4 EP2224924 A4 EP 2224924A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
cystic fibrosis
treating cystic
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08841991A
Other languages
German (de)
French (fr)
Other versions
EP2224924A1 (en
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/en
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/en
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Priority claimed from PCT/US2008/081113 external-priority patent/WO2009055671A1/en
Publication of EP2224924A1 publication Critical patent/EP2224924A1/en
Publication of EP2224924A4 publication Critical patent/EP2224924A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
EP08841991A 2007-10-25 2008-10-24 Compositions and methods for treating cystic fibrosis Withdrawn EP2224924A4 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US98272007P 2007-10-25 2007-10-25
US98271907P 2007-10-25 2007-10-25
PCT/US2007/082580 WO2008052145A2 (en) 2006-10-25 2007-10-25 Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
PCT/US2007/082581 WO2008115290A2 (en) 2006-10-25 2007-10-25 Methods of wound care and treatment
PCT/US2007/082578 WO2008052143A2 (en) 2006-10-25 2007-10-25 Mixing device and output fluids of same
US4834708P 2008-04-28 2008-04-28
US4834008P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
US4833208P 2008-04-28 2008-04-28
PCT/US2008/081113 WO2009055671A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating cystic fibrosis

Publications (2)

Publication Number Publication Date
EP2224924A1 EP2224924A1 (en) 2010-09-08
EP2224924A4 true EP2224924A4 (en) 2011-01-12

Family

ID=42261767

Family Applications (3)

Application Number Title Priority Date Filing Date
EP08842968A Withdrawn EP2215260A4 (en) 2007-10-25 2008-10-23 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP08841991A Withdrawn EP2224924A4 (en) 2007-10-25 2008-10-24 Compositions and methods for treating cystic fibrosis
EP08841701.9A Active EP2214707B1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08842968A Withdrawn EP2215260A4 (en) 2007-10-25 2008-10-23 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08841701.9A Active EP2214707B1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation

Country Status (8)

Country Link
EP (3) EP2215260A4 (en)
JP (6) JP5613565B2 (en)
CN (5) CN101910412B (en)
AU (3) AU2008316794B2 (en)
CA (3) CA2703672A1 (en)
IL (3) IL205317A (en)
MX (3) MX2010004563A (en)
WO (1) WO2009055614A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
AU2007308840C1 (en) 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
AU2007308838B2 (en) 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
EP2207669A4 (en) * 2007-10-25 2011-11-02 Revalesio Corp Bacteriostatic or bacteriocidal compositions and methods
JP5613565B2 (en) * 2007-10-25 2014-10-22 リバルシオ コーポレイション Compositions and methods for modulating cell membrane-mediated intracellular signaling
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
MX337862B (en) * 2008-04-28 2016-03-16 Revalesio Corp Compositions and methods for treating multiple sclerosis.
CN103919804A (en) 2008-05-01 2014-07-16 利发利希奥公司 Compositions And Methods For Treating Digestive Disorders
BRPI0920430A2 (en) * 2008-10-22 2019-09-24 Revalesio Corp compositions and methods for treating matrix metalloproteinase 9 (mmp9) mediated conditions
JP2012525396A (en) * 2009-04-27 2012-10-22 レバレジオ コーポレイション Compositions and methods for treating insulin resistance and diabetes mellitus
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
EP2566460A4 (en) 2010-05-07 2015-12-23 Revalesio Corp Compositions and methods for enhancing physiological performance and recovery time
KR101801864B1 (en) 2010-06-16 2017-11-27 인플래머토리 리스폰스 리서치, 아이엔씨. Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
JP2013533320A (en) 2010-08-12 2013-08-22 レバレジオ コーポレイション Compositions and methods for treating tauopathy
MX2013001749A (en) * 2010-08-13 2014-03-05 Revalesio Corp Compositions and methods for treating cardiovascular disease.
CA2831606A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
JP6368459B2 (en) * 2012-06-14 2018-08-01 松本　高明 Method for producing ophthalmic solution
AU2014249534B2 (en) 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
CA2901421A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of autoimmune disorders
EP2969002B8 (en) 2013-03-13 2018-02-21 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
JP2017526728A (en) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Levocetirizine and montelukast in the treatment of inflammation-mediated conditions
CN106943593A (en) * 2017-03-24 2017-07-14 浙江中医药大学 Application of the anti-TSLP antibody in the chronic itch medicine of preventing and treating is prepared
CN110769840A (en) * 2017-05-23 2020-02-07 碧澳维特澳大利亚股份有限公司 Extract derived from Arthrospira and use thereof
CN112305153B (en) * 2020-10-16 2022-09-23 中石化石油工程技术服务有限公司 Automatic analysis detector for bentonite content and detection method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040129112A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Metal-containing materials
WO2005113026A2 (en) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518483D0 (en) * 1995-09-09 1995-11-08 Thompson Royce Ltd Lighting control systems
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
ATE474852T1 (en) * 1998-07-28 2010-08-15 Univ California NUCLEIC ACIDS THAT CODE FOR A RECEPTOR COUPLED TO A G-PROTEIN INVOLVED IN SENSORY TRANSDUCTION
JP2003514646A (en) * 1999-10-26 2003-04-22 バイオ−ハイドレイション リサーチ ラブ， インコーポレイテッド Microcluster liquids and methods of making and using them
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
JP2003516150A (en) * 1999-12-08 2003-05-13 ジェンセット Full-length human cDNA encoding a cryptic secretory protein
US20020107197A1 (en) * 2000-09-20 2002-08-08 Yan Xu Ligands for G protein coupled receptors and methods of using them
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
CA2436427A1 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
DE10227818A1 (en) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gas enrichment modules
WO2004022098A1 (en) * 2002-09-09 2004-03-18 Borsos Ferenc Oxygen-enriched water, treated within a magnetic field and heavy water
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
BRPI0416319A (en) * 2003-11-10 2007-01-09 Merck & Co Inc compound, pharmaceutical composition, methods of treating or preventing pain, syndromes, and disease, and methods of administering local anesthesia, and for neuroprotection under ischemic conditions.
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
WO2006103691A1 (en) * 2005-03-28 2006-10-05 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (ii) antitumour agents
DK1901749T3 (en) * 2005-05-18 2016-10-24 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones AND USES THEREOF
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2667614A1 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Method of wound care and treatment
AU2007308840C1 (en) * 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
JP5613565B2 (en) * 2007-10-25 2014-10-22 リバルシオ コーポレイション Compositions and methods for modulating cell membrane-mediated intracellular signaling
EP2207669A4 (en) * 2007-10-25 2011-11-02 Revalesio Corp Bacteriostatic or bacteriocidal compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040129112A1 (en) * 2000-07-27 2004-07-08 Gillis Scott H. Metal-containing materials
WO2005113026A2 (en) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILL S ET AL: "Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - A review", JOURNAL OF BIOMEDICAL NANOTECHNOLOGY 200706 US LNKD- DOI:10.1166/JBN.2007.015, vol. 3, no. 2, June 2007 (2007-06-01), pages 107 - 119, XP009141494, ISSN: 1550-7033 *
See also references of WO2009055671A1 *

Also Published As

Publication number Publication date
CN104771758A (en) 2015-07-15
CA2703739A1 (en) 2009-04-30
JP5911197B2 (en) 2016-04-27
WO2009055614A1 (en) 2009-04-30
JP2014169328A (en) 2014-09-18
EP2214707A4 (en) 2011-04-20
AU2008316794B2 (en) 2015-04-23
IL205319A0 (en) 2010-12-30
IL205318A0 (en) 2010-12-30
CN103933567A (en) 2014-07-23
JP2011500844A (en) 2011-01-06
AU2008316663B2 (en) 2014-12-18
JP5869763B2 (en) 2016-02-24
JP2011500847A (en) 2011-01-06
JP2014205693A (en) 2014-10-30
EP2214707B1 (en) 2017-07-12
CN101909648A (en) 2010-12-08
CN101910412B (en) 2013-08-21
CA2703754A1 (en) 2009-04-30
AU2008316623A1 (en) 2009-04-30
CA2703672A1 (en) 2009-04-30
AU2008316663A1 (en) 2009-04-30
JP2011500837A (en) 2011-01-06
AU2008316623B2 (en) 2015-01-22
CN101909623A (en) 2010-12-08
CN101909623B (en) 2015-04-01
IL205317A0 (en) 2010-12-30
MX2010004563A (en) 2010-07-28
IL205318A (en) 2017-01-31
EP2224924A1 (en) 2010-09-08
JP5613565B2 (en) 2014-10-22
CA2703754C (en) 2019-04-09
CN101910412A (en) 2010-12-08
EP2215260A4 (en) 2011-04-20
JP2014193915A (en) 2014-10-09
EP2214707A1 (en) 2010-08-11
MX2010004564A (en) 2010-07-28
IL205319A (en) 2016-06-30
IL205317A (en) 2016-03-31
MX2010004554A (en) 2010-07-28
EP2215260A1 (en) 2010-08-11
AU2008316794A1 (en) 2009-04-30
CN101909648B (en) 2014-04-16

Similar Documents

Publication Publication Date Title
EP2224924A4 (en) Compositions and methods for treating cystic fibrosis
HRP20190214T1 (en) Compositions and methods for treating purpura
EP2170309A4 (en) Methods and compositions for treating disorders
EP2120561A4 (en) Compositions for treating biofilms and methods for using same
ZA201001300B (en) Antigen-asjuvant compositions and methods
EP2124985A4 (en) Methods and compositions for treating neuropathies
IL185540A0 (en) Compositions and methods for treating acne
IL186599A0 (en) Methods for treating and preventing fibrosis
EP1986952A4 (en) Methods of treating cystic fibrosis
IL202184A0 (en) Methods and compositions for increased transgene expression
GB2466912B (en) Compositions and methods for treating lysosomal disorders
EP1981491A4 (en) Formulations and methods for treating dry eye
HK1165293A1 (en) Composition for the treatment of cystic fibrosis
IL210097A0 (en) Compositions and methods for treating unfluenza
ZA200900140B (en) Methods and compositions for treating biofilms
GB0906630D0 (en) Compositions and method for hair loss prevention
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
PT2007895E (en) Compositions and methods for therapy of cystic fibrosis
GB0721291D0 (en) Methods and compositions
EP2182943A4 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists
GB0619500D0 (en) Treatment of fibrosis
EP2057179A4 (en) Compositions and methods for treating myelosuppression
GB0719526D0 (en) Compositions and methods
EP2170314A4 (en) Methods and compositions for treating phenylketonuria
EP2094279A4 (en) Methods and compositions for treating influenza

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20101213

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140822

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160927